Objective To evaluate the effect of conformal radiotherapy for elderly patients with adva nced non-small-cell lung cancer. Methods From November 1998 to June 2001, 24 elderly patients with advanced non-small -cell lung cancer were treated with conformal radiotherapy. ResultsOne-year, two-year and three-year overall survival rate for the entire group are 91 67%, 54 16%, 43 33%. No patients developed acute radiation pneumonitis . According to the univariate analysis, significant prognostic factors included superior vena cava syndrome, Karnofsky performance status scores and gross tumo r volume. Conclusions Conformal radiotherapy improve the effect in elderly patients with advanced no n-small-cell lung cancer.

Objective To evaluate the dose response and prognosis of patients with stage ⅠE primary ocular adnexal mucosa associated lymphoid tissue lymphoma (POAml) treated with radiotherapy.Methods Clinical date of 93 patients (117 eyes) with stage ⅠE POAml treated from November 2003 to July 2015 were retrospectively analyzed.The dose response was evaluated by observing the ocular changes in exophthalmos.The survival rate was calculated by using the Kaplan-Meier survival analysis.The log-rank test and univariate analysis were used for prognostic analysis.Results For patients treated with a dose of ≥ 27 Gy,the response rate of exophthalmos was 69.0％(29/42).The median response dose was 7.2 Gy (5.4-19.8 Gy).For all patients,the local control rate was 100％.The 5-and 10-year overall survival (OS) rates were 92％ and 82％.The 5-and 10-year cause-specific survival (CSS) rates were equally 98％.The 5-and 10-year progression-free survival (PFS) rate were 90％ and 88％.The univariate prognostic analysis demonstrated that the International Prognostic Index (IPI) score and age were the prognostic factors of PFS rate (both P=0.04).Conclusions POAml is sensitive to radiation therapy.Radiotherapy alone can yield excellent local control and long-term survival in POAml patients.A prescription dosage of 18 Gy dose can obtain favorable clinical efficacy.